Pfizer and BioNTech Have Launched Trials for Omicron Vaccine

Pfizer Acquires Wyeth For $68 Billion

Photo: Getty Images

Pfizer and BioNTech has announced that they have commenced a clinical trial testing a COVID-19 vaccine that aims to protect against the Omicron variant. 

Pfizer and BioNTech have hopes of enrolling approximately 1,420 healthy adults, ranging in age from 18-55 years old to participate in this trial. The trial anticipates to see if this vaccine is safe and whether it will provide an immune response in the individual. 

Participants taking part in the trial will be divided in three groups – those groups are “fully vaccinated”, “fully vaccinated and boosted”, and “unvaccinated”. 

The medical giants are also hoping to start a similar study in the United States for those older than 55 years old. 

Studies conducted by the CDC show that the current booster shot offers “significant protection” against COVID-19 and symptomatic illness. That being said, protection against the Delta variant was higher compared to protection against the Omicron variant. 

Sponsored Content

Sponsored Content